I. Roots

发表

Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.

R. Kaiser, P. Tremblay, O. Sezer, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Protective role of glutathione S-transferase P1 (GSTP1) Val105Val genotype in patients with bronchial asthma.

I. Roots, A. Aynacioglu, M. Nacak, 2003, British journal of clinical pharmacology.

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

J Licinio, J Kirchheiner, M. Wong, 2004, Molecular Psychiatry.

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.

J. Brockmöller, I. Roots, C. Sachse, 1997, American journal of human genetics.

Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn’s disease

C. Meisel, C. Büning, I. Roots, 2007, European Journal of Clinical Pharmacology.

Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis.

U. Brinkmann, M. Fromm, M. Eichelbaum, 2003, Gastroenterology.

Interaction of CA repeat polymorphism of the endothelial nitric oxide synthase and hyperhomocysteinemia in acute coronary syndromes: evidence of gender-specific differences

M. Laule, G. Baumann, K. Stangl, 2003, Journal of Molecular Medicine.

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.

C. Meisel, J. Brockmöller, I. Roots, 2003, British journal of clinical pharmacology.

Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics

Steffen Bauer, Andreas Johne, I. Roots, 2004, Clinical pharmacology and therapeutics.

Genetic polymorphisms in endothelin-receptor-subtype-a-gene as susceptibility factor for obstructive sleep apnea syndrome.

T. Penzel, I. Fietze, I. Roots, 2010, Sleep medicine.

Effects of the CYP2D6 Gene Duplication on the Pharmacokinetics and Pharmacodynamics of Tramadol

J. Brockmöller, I. Roots, J. Kirchheiner, 2008, Journal of clinical psychopharmacology.

Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication

J Kirchheiner, J Lötsch, J. Lötsch, 2007, The Pharmacogenomics Journal.

Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene

U. Brinkmann, M. Fromm, C. Meisel, 2002, Clinical pharmacology and therapeutics.

Below median birth weight in appropriate-for-gestational-age preterm infants as a risk factor for bronchopulmonary dysplasia

W. Hopfenmüller, I. Roots, M. Vogel, 2008, Journal of perinatal medicine.

Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy.

U. Brinkmann, M. Eichelbaum, I. Roots, 2001, Drug discovery today.

Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients.

I. Roots, K. Püchler, B. Sierakowski, 1998, British journal of clinical pharmacology.

[Levosimendan. Clinical indications of a new vasoactive substance].

C. Spies, I. Roots, W. Kox, 2004, Der Anaesthesist.

Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.

P Vineis, R. Hayes, M. García-Closas, 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Association of NAT 1 and NAT 2 Polymorphisms to Urinary Bladder Cancer : Significantly Reduced Risk in Subjects with NAT 1 * 10 1

J. Brockmöller, I. Roots, I. Cascorbi, 2001 .

Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.

J. Brockmöller, I. Roots, I. Cascorbi, 2001, Cancer research.

Polymorphic arylamine N‐acetyltransferase (NAT2) genes in children with insulin‐dependent diabetes mellitus

I. Roots, N. Drakoulis, P. Mrozikiewicz, 1994, Clinical pharmacology and therapeutics.

Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.

J. Brockmöller, K. Sperling, I. Roots, 1995, American journal of human genetics.

Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene

I. Roots, K. Oselin, P. Mrozikiewicz, 2003, European Journal of Clinical Pharmacology.

Polymorphisms in xenobiotic conjugation and disease predisposition.

J. Brockmöller, I. Roots, I. Cascorbi, 1998, Toxicology letters.

Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer.

J. Brockmöller, I. Roots, I. Cascorbi, 1996, Cancer research.

Correlation between trans-stilbene oxide-glutathione conjugation activity and the deletion mutation in the glutathione S-transferase class mu gene detected by polymerase chain reaction.

J. Brockmöller, I. Roots, R. Kerb, 1992, Biochemical pharmacology.

Genetic variants of the insulin receptor substrate‐1 are influencing the therapeutic efficacy of oral antidiabetics

I. Roots, A. Seeringer, J. Kirchheiner, 2010, Diabetes, obesity & metabolism.

Hydrogen peroxide in hepatic microsomes.

I. Roots, G. Heinemeyer, A. Hildebrandt, 1978, Methods in enzymology.

A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study

M. Laule, G. Baumann, K. Stangl, 1999, The Lancet.

MDR1 Haplotypes Do Not Affect the Steady‐State Pharmacokinetics of Cyclosporine in Renal Transplant Patients

K. Budde, I. Roots, A. Johne, 2003, Journal of clinical pharmacology.

Interaction of cyclosporin and calcium antagonists.

I. Roots, H. Neumayer, T. Philipp, 1989, Transplantation proceedings.

Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients.

T. Strom, I. Roots, G. Walz, 1991, Transplantation.

St John’s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive

I. Roots, S. Bauer, A. Brattström, 2009, European Journal of Clinical Pharmacology.

St John’s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive

I. Roots, S. Bauer, A. Brattström, 2009, European Journal of Clinical Pharmacology.

The β3-adrenergic receptor Trp64Arg mutation is not associated with coronary artery disease

M. Laule, G. Baumann, K. Stangl, 2001 .

Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.

C. Meisel, J. Brockmöller, I. Roots, 2004, Pharmacogenetics.

Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics

K. Wernecke, J. Brockmöller, I. Roots, 2003, Journal of clinical psychopharmacology.

Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.

J. Sasse, J. Brockmöller, I. Roots, 2003, Pharmacogenetics.

Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.

J. Brockmöller, I. Roots, I. Meineke, 2002, Pharmacogenetics.

Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.

C. Meisel, J. Brockmöller, I. Roots, 2000, Pharmacogenomics.

Genotype and phenotype relationship in drug metabolism.

J. Brockmöller, I. Roots, I. Cascorbi, 2007, Ernst Schering Research Foundation workshop.

Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6.

J. Brockmöller, A. Rolfs, I. Roots, 2000, Pharmacopsychiatry.

Fifteen polymorphisms in endothelin-1, endothelin-2 and endothelin-receptor-A genotyped by four duplex assays and seven simple assays on a LightCycler using hybridization probes

K. Stangl, O. Landt, I. Roots, 2006, Clinical chemistry and laboratory medicine.

Pharmacodynamic Monitoring of Mycophenolate Mofetil

K. Budde, I. Roots, P. Glander, 2000, Clinical chemistry and laboratory medicine.

Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1).

J. Brockmöller, I. Roots, I. Cascorbi, 1999, Biochemical pharmacology.

Urinary 6 beta-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment.

U. Mansmann, I. Roots, K. Rost, 1997, International journal of clinical pharmacology and therapeutics.

Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus.

I. Roots, I. Cascorbi, F. Hiepe, 2002, Pharmacogenetics.

Ml and Its Variants A and B as Host Factors of Bladder Cancer Susceptibility: A Case-Control Study

I. Roots, R. Kerb, N. Drakoulis, 2006 .

High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes.

H. Bartsch, A. Kopp-Schneider, J. Brockmöller, 1998, Pharmacogenetics.

Hyperhomocysteinaemia and adverse events complicating coronary catheter interventions.

T. Dschietzig, C. Richter, M. Laule, 2000, International journal of cardiology.

A1166C polymorphism of the angiotensin II type 1 receptor gene and risk of adverse events after coronary catheter interventions.

M. Laule, G. Baumann, K. Stangl, 2000, American Heart Journal.

Genotype and Phenotype of Glutathione S-Transferase Class µ Isoenzymes µ and ψ in Lung Cancer Patients and Controls

J. Brockmöller, I. Roots, R. Kerb, 1993 .

Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia

R. Kaiser, J. Brockmöller, I. Roots, 2000, Molecular Psychiatry.

Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene

I. Roots, K. Oselin, P. Mrozikiewicz, 2003, European Journal of Clinical Investigation.

Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes

U. Brinkmann, M. Laule, K. Stangl, 2007, Pharmacogenetics and genomics.

Pharmacokinetics of Levetiracetam in Patients with Moderate to Severe Liver Cirrhosis (Child‐Pugh Classes A, B, and C): Characterization by Dynamic Liver Function Tests

J. Brockmöller, I. Roots, H. Lochs, 2005, Clinical pharmacology and therapeutics.

Induction of CYP1A by various benzimidazoles and its significance in administrative drug regulation.

J. Brockmöller, I. Roots, K. Ruckpaul, 1999, Drug metabolism reviews.

Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population.

I. Roots, I. Cascorbi, A. Aynacioglu, 1997, Pharmacogenetics.

NAT2*12A (803A-->G) codes for rapid arylamine n-acetylation in humans.

J. Brockmöller, I. Roots, I. Cascorbi, 1996, Pharmacogenetics.

Determination and allelic allocation of seven nucleotide transitions within the arylamine N‐acetyltransferase gene in the Polish population

J. Brockmöller, I. Roots, I. Cascorbi, 1996, Clinical pharmacology and therapeutics.

Critical evaluation of the effect of valerian extract on sleep structure and sleep quality.

I. Fietze, I. Roots, K. Diefenbach, 2000, Pharmacopsychiatry.

Determination of S-carboxymethyl-L-cysteine and some of its metabolites in urine and serum by high-performance liquid chromatography using fluorescent pre-column labelling.

J. Brockmöller, I. Roots, B. Staffeldt, 1991, Journal of chromatography.

Elevated serum leptin in patients with coronary artery disease: no association with the Trp64Arg polymorphism of the β3-adrenergic receptor

M. Laule, G. Baumann, K. Stangl, 2000, International Journal of Obesity.

Influence of GSTT1 and GSTM1 Genotypes on Sunburn Sensitivity

U. Brinkmann, J. Brockmöller, I. Roots, 2002, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

Possible control of hydrogen peroxide production and degradation in microsomes during mixed function oxidation reaction.

I. Roots, A. Hildebrandt, M. Speck, 1973, Biochemical and biophysical research communications.

Recalling P446. P4501A1 (CYP1A1) Opting for Clinical Application

I. Roots, D. Schwarz, A. Hildebrandt, 2007, Drug metabolism reviews.

Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany.

I. Roots, I. Cascorbi, K. Golka, 1996, Scandinavian journal of work, environment & health.

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.

R. Kaiser, J. Brockmöller, P. Tremblay, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Role of Pharmacogenetics in Drug Epidemiology

I. Roots, N. Drakoulis, G. Heinemeyer, 1987 .

Determination of Glutathione S-Transferase u Genotype in Humans by PCR-Amplified Gene-Probes

J. Brockmöller, I. Roots, N. Drakoulis, 1991 .

Hypericin and Pseudohypericin: Pharmacokinetics and Effects on Photosensitivity in Humans

J. Brockmöller, I. Roots, R. Kerb, 1997, Pharmacopsychiatry.

Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43.

I. Roots, U. Kleeberg, S. Krusekopf, 2003, European journal of pharmacology.

Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19

R. Kaiser, J. Lötsch, M. Montemurro, 2005, The Pharmacogenomics Journal.

Hyperforin content determines the magnitude of the St John's Wort–cyclosporine drug interaction

K. Budde, I. Roots, B. Uehleke, 2004, Clinical pharmacology and therapeutics.

Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients.

K. Budde, I. Roots, H. Neumayer, 2003, British journal of clinical pharmacology.

Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients.

K. Budde, I. Roots, S. Bauer, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Decreased Plasma Levels of Amitriptyline and Its Metabolites on Comedication With an Extract From St. John’s Wort (Hypericum perforatum)

J. Brockmöller, I. Roots, S. Bauer, 2002, Journal of clinical psychopharmacology.

Differential effects of Saint John's Wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6β-hydroxycortisol in healthy volunteers

J. Brockmöller, I. Roots, R. Kerb, 2002, European Journal of Clinical Pharmacology.

Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin.

K. Budde, I. Roots, H. Neumayer, 2000, International journal of clinical pharmacology and therapeutics.

Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin’s cholesterol lowering capabilities and basal sterol serum levels

I. Roots, J. Mwinyi, T. Sudhop, 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

Studies on the mechanism of stimulation of microsomal H2O2 formation and benzo(a)pyrene hydroxylation by substrates and flavone.

I. Roots, G. Heinemeyer, C. Bergs, 1981, Advances in experimental medicine and biology.

Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes.

O. Landt, I. Roots, K. Diefenbach, 2004, Analytical biochemistry.

Rapid genotyping of melanocortin-1 receptor with use of fluorescence-labeled oligonucleotides.

O. Landt, I. Roots, K. Diefenbach, 2003, Clinical chemistry.

Pitfalls in N-acetyltransferase 2 genotyping.

I. Roots, I. Cascorbi, 1999, Pharmacogenetics.

Pharmakogenetik als Basis neuer Therapiekonzepte

I. Roots, M. Goldammer, R. Kaiser, 2003, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia

R. Kaiser, J. Brockmöller, P. Tremblay, 2002, Molecular Psychiatry.

Mutations in the human paraoxonase 1 gene: frequencies, allelic linkages, and association with coronary artery disease.

M. Laule, G. Baumann, K. Stangl, 1999, Pharmacogenetics.

Role of Kozak sequence polymorphism of platelet glycoprotein Ibalpha as a risk factor for coronary artery disease and catheter interventions.

M. Laule, G. Baumann, K. Stangl, 2001, Journal of the American College of Cardiology.

Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen.

C. Meisel, I. Roots, A. Johne, 2003, Atherosclerosis.

Rapid quantification of CYP3A4 expression in human leukocytes by real-time reverse transcription-PCR.

J. Brockmöller, I. Roots, P. Mrozikiewicz, 2002, Clinical chemistry.

Implications of pharmacogenetics for individualizing drug treatment and for study design

C. Meisel, J. Brockmöller, I. Roots, 2003, Journal of Molecular Medicine.

Genetic variants in FKBP5 affecting response to antidepressant drug treatment.

J. Sasse, J. Brockmöller, I. Roots, 2008, Pharmacogenomics.

Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the beta2-adrenergic receptor among Turks.

J. Brockmöller, I. Roots, I. Cascorbi, 1999, British journal of clinical pharmacology.

Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists.

R. Kaiser, J. Brockmöller, P. Tremblay, 2004, Pharmacogenetics.

Flavin monooxygenase 3 (FMO3) polymorphism in a white population: Allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism

I. Roots, C. Sachse, S. Bauer, 1999, Clinical pharmacology and therapeutics.

Concordance between enzyme activity and genotype of glutathione S-transferase theta (GSTT1).

J. Brockmöller, I. Roots, R. Kerb, 1998, Biochemical pharmacology.

Variations i n t he 5 -Hydroxytryptam ine T ype 3 B R eceptor G ene as P redictors o f t he E fficacy o f A ntiemetic T reatment i n Cancer P atients

R. Kaiser, P. Tremblay, O. Sezer, 2003 .

Reduced procedural risk for coronary catheter interventions in carriers of the coagulation factor VII-Gln353 gene.

M. Laule, G. Baumann, K. Stangl, 2000, Journal of the American College of Cardiology.

Paraoxonase 1 mutations in a Turkish population.

I. Roots, I. Cascorbi, A. Aynacioglu, 1999, Toxicology and applied pharmacology.

Deficiency of glutathione S-transferases T1 and M1 as heritable factors of increased cutaneous UV sensitivity.

J. Brockmöller, I. Roots, R. Kerb, 1997, The Journal of investigative dermatology.

Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region

J. Brockmöller, I. Roots, I. Cascorbi, 1994, The clinical investigator.

Polymorphisms in the Human Cytochrome P-450 1A1 Gene (CYP1A1) as a Factor for Developing Acne

I. Roots, C. Zouboulis, N. Drakoulis, 1998, Dermatology.

High frequency of CYP1A1 mutations in a Turkish population

I. Roots, I. Cascorbi, P. Mrozikiewicz, 1998, Archives of Toxicology.

A Polymorphism in Exon 7 of Human CYP 1 AJ : Population Frequency , Mutation Linkages , and Impact on Lung Cancer Susceptibility 1

I. Roots, I. Cascorbi, Jurgen BrockmÃ, 2022 .

A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility.

J. Brockmöller, I. Roots, I. Cascorbi, 1996, Cancer research.

Peptide nucleic acid-mediated polymerase chain reaction clamping allows allelic allocation of CYP1A1 mutations.

O. Landt, I. Roots, I. Cascorbi, 1997, Analytical biochemistry.

Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk.

I. Roots, V. Jahnke, I. Cascorbi, 1999, Pharmacogenetics.

Implication of arylamine N-acetyltransferase (NAT2) polymorphism on levels of tumour markers CEA, AFP, CA 125, CA 19.9, and CA 15.3

I. Roots, I. Cascorbi, A. Aynacioglu, 1999 .

Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone

M. Roden, I. Roots, M. Ledl, 2005, Diabetologia.

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine.

J. Brockmöller, I. Roots, C. Sachse, 1999, British journal of clinical pharmacology.

Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets

J. Brockmöller, M. Tzvetkov, I. Roots, 2005, Pharmacogenetics and genomics.

Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin

J. Brockmöller, I. Roots, R. Kerb, 1996, Antimicrobial agents and chemotherapy.

Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers.

J. Brockmöller, I. Roots, R. Kerb, 1994, Journal of geriatric psychiatry and neurology.

In vitro assessment of inhibition by natural polyphenols of metabolic activation of procarcinogens by human CYP1A1.

I. Roots, D. Schwarz, 2003, Biochemical and biophysical research communications.

Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population

A. Bozkurt, J. Brockmöller, I. Roots, 1999, Clinical pharmacology and therapeutics.

The kinetics of metamizol and its metabolites in critical-care patients with acute renal dysfunction

I. Roots, G. Heinemeyer, H. Gramm, 2004, European Journal of Clinical Pharmacology.

Functional analysis of the rat bile salt export pump gene promoter.

P. Meier, I. Roots, C. Gartung, 2002, European journal of biochemistry.

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

J. Sasse, J. Brockmöller, I. Roots, 2003, Pharmacogenetics.

Determination of hyperforin, hypericin, and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and ultraviolet detection.

I. Roots, S. Bauer, H. Graubaum, 2001, Journal of chromatography. B, Biomedical sciences and applications.

Monitoring of pentobarbital plasma levels in critical care patients suffering from increased intracranial pressure.

I. Roots, G. Heinemeyer, R. Dennhardt, 1986, Therapeutic drug monitoring.

Non-competitive and competitive inhibition of mixed function oxidase in rat liver microsomes by metyrapone

I. Roots, A. Hildebrandt, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Active centers of microsomal cytochrome P-450 determined with metyrapone by mutual depletion system kinetics

I. Roots, A. Hildebrandt, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Benzo(a)pyrene metabolism in hepatic microsomes from female DA rats with a genetic sparteine oxidation deficiency.

I. Roots, E. Schlede, 1985, Toxicology letters.

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

J. Sasse, J. Brockmöller, I. Roots, 2003, Pharmacogenetics.

Association between the N-acetylation genetic polymorphism and bronchial asthma.

I. Roots, I. Cascorbi, M. Erdal, 2002, British journal of clinical pharmacology.

The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.

J. Brockmöller, I. Roots, J. Köchling, 1992, British journal of clinical pharmacology.

Impact of the CYP2D6 Ultrarapid Metabolizer Genotype on Mirtazapine Pharmacokinetics and Adverse Events in Healthy Volunteers

J. Brockmöller, I. Roots, I. Meineke, 2004, Journal of clinical psychopharmacology.

Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk.

J. Brockmöller, I. Roots, I. Cascorbi, 1996, Cancer research.

Polymorphisms of toxifying and detoxifying hepatic enzymes in amyotrophic lateral sclerosis

J. Brockmöller, A. Ludolph, I. Roots, 2003, Journal of neurology, neurosurgery, and psychiatry.

Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.

J. Brockmöller, I. Roots, K. Rost, 1995, Pharmacogenetics.

Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls.

J. Brockmöller, I. Roots, R. Kerb, 1993, Cancer research.

Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS‐sorted peripheral blood CD4+, CD8+, CD19+, and CD56+cells

I. Roots, K. Oselin, P. Mrozikiewicz, 2003, European journal of haematology.

Omeprazole weakly inhibits CYP1A2 activity in man.

U. Fuhr, J. Brockmöller, I. Roots, 1999, International journal of clinical pharmacology and therapeutics.

Identification of twelve polymorphisms in the endothelin-1 gene by use of fluorescently labeled oligonucleotides and PCR with restriction fragment polymorphism analysis.

U. Brinkmann, K. Stangl, C. Meisel, 2004, Clinical chemistry.

HPLC-ANALYSIS OF S-CARBOXYMETHYLCYSTEINE AND ITS SULPHOXIDE METABOLITES

J. Brockmöller, I. Roots, Z. Simane, 1988, Drug metabolism and drug interactions.

CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin?

J. Brockmöller, I. Roots, J. Kirchheiner, 2008, Journal of analytical toxicology.

Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.

I. Roots, W. Lindner, B. M. Frey, 1987, The Journal of pharmacology and experimental therapeutics.

Arylamine N-acetyltransferase activity in man.

J. Brockmöller, I. Roots, I. Cascorbi, 1999, Drug metabolism reviews.

Clinical Drug Interactions with Medicinal Herbs

I. Roots, A. Johne, 2005 .

No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract.

I. Roots, K. Diefenbach, S. Bauer, 2005, Planta medica.

D-glucaric acid excretion in critical care patients--comparison with 6 beta-hydroxycortisol excretion and serum gamma-glutamyltranspeptidase activity and relation to multiple drug therapy.

I. Roots, G. Heinemeyer, R. Dennhardt, 1986, British journal of clinical pharmacology.

The inhibitory effect of metyrapone on cytochrome P-450-catalyzed mixed-function oxidation reactions as compared to the effect of carbon monoxide.

R. Estabrook, I. Roots, A. Hildebrandt, 1971, Chemico-biological interactions.

Oxidation and glucuronidation of valproic acid in male rats--influence of phenobarbital, 3-methylcholanthrene, beta-naphthoflavone and clofibrate.

H. Nau, I. Roots, G. Heinemeyer, 1985, Biochemical pharmacology.

Mono-oxygenase-Linked Hydrogen Peroxide Production and Degradation in Liver Microsomal Fractions

I. Roots, A. Hildebrandt, M. Tjoe, 1975 .

IN VIVO PARAMETERS OF DRUG METABOLISM—DIFFERENCES IN SPECIFICITY TOWARDS INDUCING AGENTS

I. Roots, A. Hildebrandt, B. Ley, 1977 .

Cyclosporin drug monitoring: Comparison of four immunoassays and HPLC

J. Brockmöller, I. Roots, G. Walz, 1989, Klinische Wochenschrift.

Moxifloxacin does not Alter Ciclosporin Pharmacokinetics in Transplant Patients

I. Roots, H. Stass, D. Kubitza, 2012 .

Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients: a multiple-dose, uncontrolled, single-centre study.

I. Roots, H. Stass, D. Kubitza, 2010, Clinical drug investigation.

Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection.

J. Brockmöller, I. Roots, J. Kirchheiner, 2003, Journal of pharmaceutical and biomedical analysis.

Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant--463A of the myeloperoxidase gene.

C. Meisel, J. Brockmöller, I. Roots, 2000, Cancer research.

Demonstration of drug-ethanol interactions by changes in activity of hepatic microsomal oxidase/oxygenase cytochrome P-450 function.

I. Roots, S. Nigam, G. Heinemeyer, 1979, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

CYP2D6 Genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting

J. Brockmöller, P. Milos, I. Roots, 2000, AAPS PharmSci.

Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)

I. Roots, S. Bauer, A. Johne, 1999, Clinical pharmacology and therapeutics.

Randomised, Double-Blind Study of the Effects of Oxybutynin, Tolterodine, Trospium Chloride and Placebo on Sleep in Healthy Young Volunteers

K. Wernecke, I. Roots, K. Diefenbach, 2003, Clinical drug investigation.

Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.

T. Penzel, I. Fietze, I. Roots, 2008, Sleep medicine.

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

U. Brinkmann, J. Brockmöller, M. Eichelbaum, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations

I. Roots, J. Mwinyi, T. Gerloff, 2008, European Journal of Clinical Pharmacology.

Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine.

J. Brockmöller, I. Roots, C. Sachse, 1998, Pharmacogenetics.

A rare insertion of T226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15.

J. Brockmöller, I. Roots, T. Reum, 1996, Pharmacogenetics.

Assessment of Liver Metabolic Function Implications

I. Roots, J. Brockmoller, 1994 .

Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation.

U. Brinkmann, J. Brockmöller, I. Roots, 2000, Pharmacogenetics.

Validity of PCR with emphasis on variable number of tandem repeat analysis.

R. Kaiser, J. Brockmöller, P. Tremblay, 2002, Clinical biochemistry.

Beta 2-adrenergic receptor polymorphism and susceptibility to primary congenital and primary open angle glaucoma

J. Brockmöller, I. Roots, I. Cascorbi, 2003, European Journal of Clinical Pharmacology.

Impact of Myeloperoxidase and NADPH-Oxidase Polymorphisms in Drug-Induced Agranulocytosis

Michael Dettling, I. Roots, I. Cascorbi, 2004, Journal of clinical psychopharmacology.

Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 variants.

I. Roots, I. Cascorbi, W. Schunck, 2001, Carcinogenesis.

Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs

J. Brockmöller, I. Roots, J. Kirchheiner, 2005, Clinical pharmacokinetics.

Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism.

A Kopp-Schneider, H. Bartsch, A. Kopp-Schneider, 2000, Carcinogenesis.

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.

J. Brockmöller, I. Roots, A. Aynacioglu, 1999, British journal of clinical pharmacology.

Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients

J. Brockmöller, I. Roots, R. Loddenkemper, 1992, The clinical investigator.

Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects

C. Meisel, M. Eichelbaum, S. Hoffmeyer, 2001, Clinical pharmacology and therapeutics.

Short Communication A Single Nucleotide Polymorphism in the Human H-ras Proto-oncogene Determines the Risk of Urinary Bladder Cancer 1

I. Roots, A. Johne, 2003 .

A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer.

J. Brockmöller, I. Roots, A. Johne, 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer.

MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes

I. Roots, K. Oselin, T. Gerloff, 2003, Fundamental & clinical pharmacology.

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients

L Fritsche, K. Budde, I. Roots, 1999, Clinical pharmacology and therapeutics.

In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms

I. Roots, T. Gerloff, M. Schaefer, 2006, Pharmacogenetics and genomics.

MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.

K. Budde, I. Roots, E. S. Perloff, 2004, British journal of clinical pharmacology.

MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males.

Christian Meisel, Andreas Johne, C. Meisel, 2002, British journal of clinical pharmacology.

The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels

U. Brinkmann, T. Szekeres, J. Brockmöller, 2001, The Pharmacogenomics Journal.

Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine.

J. Brockmöller, I. Roots, N. Müller, 1991, Therapeutic drug monitoring.

Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2

C. Meisel, J. Brockmöller, I. Roots, 2002, Clinical pharmacology and therapeutics.

Pharmacokinetics of recombinant human erythropoietin after SC administration and in long-term IV treatment in patients on maintenance hemodialysis.

J. Brockmöller, I. Roots, H. Neumayer, 1989, Contributions to nephrology.

Antipyrine metabolite formation and excretion in patients with chronic renal failure

N. Vermeulen, I. Roots, D. Breimer, 2004, European Journal of Clinical Pharmacology.

Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study.

J. Brockmöller, I. Roots, R. Kerb, 1994, Cancer research.

CYP1A1 genotype-selective inhibition of benzo[a]pyrene activation by quercetin.

I. Roots, D. Schwarz, P. Kisselev, 2005, European journal of cancer.

St. John's wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1.

I. Roots, D. Schwarz, P. Kisselev, 2003, Cancer research.

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment

J. Brockmöller, I. Roots, J. Kirchheiner, 2002, Clinical pharmacology and therapeutics.

Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population

J. Brockmöller, I. Roots, I. Cascorbi, 2003, European Journal of Clinical Pharmacology.

Nonlinear kinetics after high‐dose omeprazole caused by saturation of genetically variable CYP2C19

I. Roots, K. Rost, K L Rost, 1996, Hepatology.

Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro

J. Brockmöller, I. Roots, E. Störmer, 2000, Psychopharmacology.

Prediction of aryl hydrocarbon receptor-mediated enzyme induction of drugs and chemicals by mRNA quantification.

J. Brockmöller, I. Roots, R. Frötschl, 1998, Chemical research in toxicology.

Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer.

R. Kaiser, J. Brockmöller, I. Roots, 1996, Pharmacogenetics.

Multiple‐dose pharmacokinetics of ganglioside GM1 after intravenous and intramuscular administration to healthy volunteers

J. Brockmöller, I. Roots, W. Weber, 1991, Clinical pharmacology and therapeutics.

Co-expression of human cytochrome P4501A1 (CYP1A1) variants and human NADPH-cytochrome P450 reductase in the baculovirus/ insect cell system

I. Roots, I. Cascorbi, H. Honeck, 2001, Xenobiotica; the fate of foreign compounds in biological systems.

St. John's wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways

I. Roots, S. Krusekopf, 2005, Pharmacogenetics and genomics.

How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and Transport

U. Brinkmann, C. Meisel, J. Brockmöller, 2000, Clinical chemistry and laboratory medicine.

Debrisoquine phenotyping in epileptic patients treated with phenytoin and carbamazepine

I. Roots, C. Cornaggia, G. Heinemeyer, 1985 .

Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry.

I. Roots, I. Cascorbi, M. Dettling, 2001, Pharmacogenetics.

Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity.

J. Brockmöller, I. Roots, I Roots, 2000, British journal of clinical pharmacology.

Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers

J. Brockmöller, I. Roots, E. S. Perloff, 2004, European Journal of Clinical Pharmacology.

Epidemiological Concepts in Clinical Pharmacology

I. Roots, H. Kewitz, K. Voigt, 1987, Springer Berlin Heidelberg.

CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages

S. Kasper, J. Brockmöller, I. Roots, 2001, Acta psychiatrica Scandinavica.

Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter.

A. Berghöfer, R. Kaiser, J. Brockmöller, 2002, American journal of medical genetics.

Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia

B Müller-Oerlinghausen, R. Kaiser, J. Brockmöller, 2001, Molecular Psychiatry.

Wort Extracts and Some of Their Constituents Potently Inhibit Ultimate Carcinogen Formation from Benzo [ a ] pyrene-7 , 8-Dihydrodiol by Human CYP 1 A 1

I. Roots, D. Schwarz, P. Kisselev, 2003 .

Neurotoxicity caused by a high cyclosporine metabolite level.

J. Brockmöller, I. Roots, U. Kunzendorf, 1989, Transplantation.

Inhibition of 17β-estradiol activation by CYP1A1: genotype- and regioselective inhibition by St. John's Wort and several natural polyphenols.

I. Roots, W. Schunck, D. Schwarz, 2011, Biochimica et biophysica acta.

The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations.

J. Brockmöller, I. Roots, J. Kirchheiner, 2004, Personalized medicine.

Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone.

I. Roots, W. Schunck, D. Schwarz, 2005, Cancer research.

Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers

C. Meisel, I. Roots, U. Malzahn, 2006, European Journal of Clinical Pharmacology.

Urinary excretion ofD-glucaric acid, an indicator of drug metabolizing enzyme activity, in patients with impaired renal function

I. Roots, A. Hildebrandt, D. Kampf, 1980, European Journal of Clinical Pharmacology.

Kinetics of hexobarbital and dipyrone in critical care patients receiving high-dose pentobarbital

I. Roots, G. Heinemeyer, H. Gramm, 2004, European Journal of Clinical Pharmacology.

Evaluation ofin vivo parameters of drug metabolizing enzyme activity in man after administration of clemastine, phenobarbital or placebo

I. Roots, A. Hildebrandt, H. Kewitz, 1975, European Journal of Clinical Pharmacology.

Comparison of methods to study enzyme induction in man.

I. Roots, A. Hildebrandt, K. Saalfrank, 1975, Advances in experimental medicine and biology.

Molecular Genetics of Cancer Susceptibility

C. Meisel, J. Brockmöller, I. Roots, 2000, Pharmacology.

Human CYP1A1 allelic variants: baculovirus expression and purification, hydrodynamic, spectral, and catalytical properties and their potency in the formation of all-trans-retinoic acid.

J. Behlke, I. Roots, W. Schunck, 2003, Protein expression and purification.

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol Pharmacokinetics and Pharmacodynamics

C. Meisel, J. Brockmöller, M. Tzvetkov, 2004, Clinical pharmacology and therapeutics.

Pharmacogenetics‐Based New Therapeutic Concepts

Rolf Kaiser, Christian Meisel, Jürgen Brockmöller, 2004, Drug metabolism reviews.

Single-dose pharmacokinetics of temocapril and temocapril diacid in subjects with varying degrees of renal impairment

I. Roots, K. Püchler, B. Sierakowski, 1997, European Journal of Clinical Pharmacology.

Enzyme catalysed cleavage of the N-N bond of N-nitrosamines.

I. Roots, K. Appel, A. Hildebrandt, 1986, Advances in experimental medicine and biology.

l -Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism

A. Kupsch, R. Kaiser, J. Brockmöller, 2003, Neurology.

Endothelin-1 Gene Variant Lys198Asn and Plasma Endothelin Level in Obstructive Sleep Apnea

T. Penzel, I. Fietze, I. Roots, 2008, Cardiology.

Systematic analysis of sequence variability of the endothelin-1 gene: a prerequisite for association studies.

K. Stangl, C. Meisel, I. Fietze, 2006, Genetic testing.

Epoxidation of benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 in reconstituted membranes. Effects of charge and nonbilayer phase propensity of the membrane.

I. Roots, W. Schunck, D. Schwarz, 2002, European journal of biochemistry.

Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin

J. Brockmöller, I. Roots, H. Neumayer, 1990 .

Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid.

Spencer S. Ericksen, I. Roots, G. Szklarz, 2004, Biochemical pharmacology.

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol‐lowering activity of (−)‐3s,5r‐fluvastatin and (+)‐3r,5s‐fluvastatin in healthy volunteers

Christian Meisel, Steffen Bauer, Jürgen Brockmöller, 2003, Clinical pharmacology and therapeutics.

Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns.

I. Roots, W. Schunck, D. Schwarz, 2005, Biochemical and biophysical research communications.

Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity.

I. Roots, I. Cascorbi, W. Schunck, 2000, Pharmacogenetics.

The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.

I. Roots, J. Sehouli, T. Siepmann, 2016, Gynecologic oncology.

Impact of the CYP2D6 ultra‐rapid metabolizer genotype on CIS‐ and trans‐doxepin pharmacokinetics and serotonin concentration in platelets

J. Brockmöller, I. Roots, I. Meineke, 2005 .

Quantification of the antipsychotics flupentixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection.

J. Brockmöller, I. Roots, S. Bauer, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Simultaneous determination of ondansetron and tropisetron in human plasma using HPLC with UV detection.

R. Kaiser, J. Brockmöller, P. Tremblay, 2002, Biomedical chromatography : BMC.

Pharmacokinetic interaction between cyclosporin and diltiazem

J. Brockmöller, I. Roots, H. Neumayer, 2004, European Journal of Clinical Pharmacology.

Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells.

K. Budde, I. Roots, P. Glander, 2001, Clinical biochemistry.

High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease.

M. Laule, G. Baumann, K. Stangl, 2000, Pharmacogenetics.

A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment

J. Sasse, J. Brockmöller, I. Roots, 2007, The Pharmacogenomics Journal.

Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.

C. Meisel, J. Brockmöller, I. Roots, 2003, Pharmacogenetics.

Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+-ATPase inhibitors and other xenobiotics

I. Roots, A. Hildebrandt, U. Kleeberg, 2003, Xenobiotica; the fate of foreign compounds in biological systems.

Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged ≥ 50 years

I. Roots, K. Diefenbach, U. Schwantes, 2005, BJU international.

Relative Impact of Genotype and Enzyme Induction on the Metabolic Capacity of CYP2C9 in Healthy Volunteers

J. Brockmöller, I. Roots, S. Vormfelde, 2009, Clinical pharmacology and therapeutics.

Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment

J. Brockmöller, M. Tzvetkov, I. Roots, 2008, Pharmacogenetics and genomics.

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

Wolfgang Rohde, Christian Meisel, Steffen Bauer, 2002, Clinical pharmacology and therapeutics.

Quantification of pravastatin in human plasma and urine after solid phase extraction using high performance liquid chromatography with ultraviolet detection.

I. Roots, J. Mwinyi, S. Bauer, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Cytochrome P450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: Correlation with alprazolam pharmacokinetics

J. Brockmöller, I. Roots, I. Gashaw, 2003, Clinical pharmacology and therapeutics.

Detection of the GSTM1*0 allele by long polymerase chain reaction.

J. Brockmöller, I. Roots, R. Kerb, 1999, Pharmacogenetics.

Specific and dose‐dependent enzyme induction by omeprazole in human beings

I. Roots, G. Heinemeyer, K. Rost, 1994, Hepatology.

Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test

I. Roots, K. Rost, 1994, Clinical pharmacology and therapeutics.

CYP1A1 mutations 4887A, 4889G, 5639C and 6235C in the Polish population and their allelic linkage, determined by peptide nucleic acid-mediated PCR clamping.

J. Brockmöller, I. Roots, I. Cascorbi, 1997, Pharmacogenetics.

Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C‐[N‐3‐methyl]‐caffeine breath test in poor and extensive metabolizers of S‐mephenytoin

J. Brockmöller, I. Roots, M. Scheffler, 1992, Clinical pharmacology and therapeutics.

Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection.

J. Brockmöller, I. Roots, J. Kirchheiner, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.

J. Brockmöller, I. Roots, K. Rost, 1995, Journal of hepatology.

Vitamin D receptor poly(A) microsatellite and colorectal cancer risk in Caucasians

I. Roots, Jana Flügge, G. Laschinski, 2009, International Journal of Colorectal Disease.

Vitamin D receptor haplotypes protect against development of colorectal cancer

I. Roots, U. Malzahn, M. Goldammer, 2007, European Journal of Clinical Pharmacology.

Theophylline metabolism affected by mexiletine

U. Fuhr, A. Staib, I. Roots, 1992, Clinical pharmacology and therapeutics.

MICROSOMAL ELECTRON TRANSPORT REACTIONS: THE FORMATION AND UTILIZATION OF HYDROGEN PEROXIDE AS RELATED TO ALCOHOL METABOLISM**Supported in part by a grant from the National Institutes of Health (5RO1-GM-16488).

R. Estabrook, I. Roots, A. Hildebrandt, 1977 .

Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: impact on plasma homocysteine levels and development of coronary artery disease.

M. Laule, G. Baumann, K. Stangl, 2001, Atherosclerosis.

The G protein subunit beta3 and early complications after coronary catheter interventions.

M. Laule, K. Stangl, C. Meisel, 2000, Atherosclerosis.

The platelet glycoprotein Ia C807T polymorphism as risk factor for coronary catheter interventions.

M. Laule, K. Stangl, C. Meisel, 2000, Blood.

Evaluation of possible polymorphisms in sulfoxidation of carbocystein analysed by HPLC-methods

J. Brockmöller, I. Roots, B. Staffeldt, 1990 .

Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample.

I. Roots, I. Cascorbi, M. Dettling, 2001, Archives of general psychiatry.

Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

C. Meisel, J. Brockmöller, W. Rohde, 2004, Clinical pharmacokinetics.

Stoichiometric cooperation of NADPH and hexobarbital in hepatic microsomes during the catalysis of hydrogen peroxide formation.

I. Roots, G. Heinemeyer, A. Hildebrandt, 1982, Archives of biochemistry and biophysics.

The effects of substrates of mixed function oxidase on ethanol oxidation in rat liver microsomes

I. Roots, A. Hildebrandt, M. Speck, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Quantitative determination by HPLC of urinary 6β-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs

I. Roots, G. Heinemeyer, A. Hildebrandt, 1979, European Journal of Clinical Pharmacology.

Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.

I. Roots, R. Loddenkemper, M. Koch, 1988, Klinische Wochenschrift.

Clearance of ceftriaxone in critical care patients with acute renal failure

I. Roots, W. Weber, G. Heinemeyer, 2005, Intensive Care Medicine.

Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.

Steffen Bauer, Jürgen Brockmöller, J. Brockmöller, 1999, Pharmacogenetics.

Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin

J. Brockmöller, I. Roots, R. Kerb, 1996, Antimicrobial Agents and Chemotherapy.

Molekulare Pathologie

I. Roots, J. Buchmann, K. Engellandt, 2000, Acta Chirurgica Austriaca.

Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.

J Kirchheiner, L. Bertilsson, H. Bruus, 2003, Pharmacopsychiatry.

Pharmacokinetics of Hypericin and Pseudohypericin after Oral Intake of the Hypericum Perforatum Extract LI 160 in Healthy Volunteers

J. Brockmöller, I. Roots, R. Kerb, 1994 .

Dose dependent induction of CYP1A2 activity by omeprazole (Antra).

I. Roots, M. Scheffler, K. Rost, 1992, International journal of clinical pharmacology, therapy, and toxicology.